Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia

Cited by (264)

Items 101–200 of 264

1. Lipid Nanoparticle-Mediated Delivery of mRNA Into the Mouse and Human Retina and Other Ocular Tissues
   C. Chambers, Gillian L. Soo, Abbi L. Engel, Ian A. Glass, Andrea Frassetto, Paolo G.V. Martini, Timothy J. Cherry · 2024 · Translational Vision Science & Technology
2. Mitochondrial disease, mitophagy, and cellular distress in methylmalonic acidemia
   Alessandro Luciani, Matthew C.S. Denley, Larissa P. Govers, Vincenzo Sorrentino, D. Sean Froese · 2021 · Cellular and Molecular Life Sciences
3. Genetic-Based Approaches to Inherited Metabolic Liver Diseases
   Nerea Zabaleta, Mirja Hommel, David Salas, Gloria González‐Aseguinolaza · 2019 · Human Gene Therapy
4. mRNA-based modalities for infectious disease management
   Mengjie Zhang, Abid Hussain, Haiyin Yang, Jinchao Zhang, Xing‐Jie Liang, Yuanyu Huang · 2022 · Nano Research
5. Oligodendrocyte progenitor cell-specific delivery of lipid nanoparticles loaded with Olig2 synthetically modified messenger RNA for ischemic stroke therapy
   Jian Xu, Rui Wang, Wei Luo, Xiaofan Mao, Hong Zhi Gao, Xinwei Feng, Guoqiang Chen, Zhihua Yang, Wenbin Deng, Yichu Nie · 2023 · Acta Biomaterialia
6. Gene therapy for inherited metabolic diseases
   Berna Şeker Yılmaz, Sonam Gurung, Dany P.B. Perocheau, John Robert Counsell, Julien Baruteau · 2020 · PubMed Central
7. Considerations for mRNA Product Development, Regulation and Deployment Across the Lifecycle
   John H. Skerritt · 2025 · Vaccines
8. mRNA as a Novel Treatment Strategy for Hereditary Spastic Paraplegia Type 5
   Stefan Hauser, Marion Poenisch, Yvonne Schelling, Philip Höflinger, Stefanie Schuster, Axel Teegler, Rabea Betten, Jan-Åke Gustafsson, Jeannette Hübener‐Schmid, Thomas Schlake et al. · 2019 · Molecular Therapy — Methods & Clinical Development
9. Phenylalanine hydroxylase mRNA rescues the phenylketonuria phenotype in mice
   Maximiliano L. Cacicedo, Christine Weinl-Tenbruck, Daniel Frank, María José Limeres, Sebastian Wirsching, Katja Hilbert, Mansure Abdollah Pasha Famian, Nigel Horscroft, Julia B. Hennermann, Fred Zepp et al. · 2022 · Frontiers in Bioengineering and Biotechnology
10. Development of orphan drugs for rare diseases
    Han‐Wook Yoo · 2023 · Korean Journal of Pediatrics
11. Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders
    Porkizhi Arjunan, Durga Kathirvelu, Gokulnath Mahalingam, Ashish Goel, Uday George Zacharaiah, Alok Srivastava, Srujan Kumar Marepally · 2024 · Acta Pharmaceutica Sinica B
12. mRNA therapeutics: beyond vaccine applications
    Balkrishen Bhat, Shrirang Karve, Daniel G. Anderson · 2021 · Trends in Molecular Medicine
13. Versatile enzymology and heterogeneous phenotypes in cobalamin complementation type C disease
    Anna Jael Esser, Srijan Mukherjee, Ilia А. Dereven’kov, Sergei V. Makarov, Donald W. Jacobsen, Ute Spiekerkoetter, Luciana Hannibal · 2022 · iScience
14. Advances in understanding disease mechanisms and potential treatments for Crigler–Najjar syndrome
    Giulia Bortolussi, Andrés Fernando Muro · 2018 · Expert Opinion on Orphan Drugs
15. Developing mRNA Nanomedicines with Advanced Targeting Functions
    Ji Wang, Lijun Cai, Ning Li, Zhiqiang Luo, Haozhen Ren, Bing Zhang, Yuanjin Zhao · 2025 · Nano-Micro Letters
16. mRNA therapeutics: Transforming medicine through innovation in design, delivery, and disease treatment
    Mark Akinola Ige, Xiaohu Ren, Yang Yang, Haiping Zhang, Chenguang Shen, Yushan Jiang, Junxin Li, Xiaochun Wan · 2025 · Molecular Therapy — Nucleic Acids
17. Genetic Therapy Approaches for Ornithine Transcarbamylase Deficiency
    Berna Şeker Yılmaz, Paul Gissen · 2023 · Biomedicines
18. RNA Therapeutics: A Healthcare Paradigm Shift
    Sarfaraz K. Niazi · 2023 · Biomedicines
19. Current Status of Messenger RNA Delivery Systems
    Matthew G. Stanton · 2018 · Nucleic Acid Therapeutics
20. Improved therapeutic efficacy in two mouse models of methylmalonic acidemia (MMA) using a second-generation mRNA therapy.
    Kimberly A. Coughlan, Marianne Eybye, Nicholas Henderson, Christine DeAntonis, Andrea Frassetto, Erin Hanahoe, Tatiana Ketova, Eric Jacquinet, Vladimir Presnyak, Ruchi Jain et al. · 2024 · Molecular Genetics and Metabolism
21. Current limitations of gene therapy for rare pediatric diseases: Lessons learned from clinical experience with AAV vectors
    Antoine Gardin, Giuseppe Ronzitti · 2023 · Archives de Pédiatrie
22. Development of a minimal PBPK-QSP modeling platform for LNP-mRNA based therapeutics to study tissue disposition and protein expression dynamics
    Kenji Miyazawa, Yun Liu, Hojjat Bazzazi · 2024 · Frontiers in Nanotechnology
23. RNA-based therapies in liver metabolic diseases
    Antonio Fontanellas, Pedro Berraondo, Francesco Urigo, Daniel Jericó, Paolo G.V. Martini, Fernando Pastor, Matias Antonio Avila · 2025 · Gut
24. Severity modeling of propionic acidemia using clinical and laboratory biomarkers
    Oleg A. Shchelochkov, Irini Manoli, Paul L. Juneau, Jennifer L. Sloan, Susan Ferry, Jennifer G. Myles, Megan Schoenfeld, Alexandra R. Pass, Samantha McCoy, Carol Van Ryzin et al. · 2021 · Genetics in Medicine
25. Chemically modified mRNA beyond COVID-19: Potential preventive and therapeutic applications for targeting chronic diseases
    Dana H. Elkhalifa, Menatallah Rayan, Ahmed T. Negmeldin, Abdelbary M. A. Elhissi, Ashraf A. Khalil · 2021 · Biomedicine & Pharmacotherapy
26. mRNA delivery technologies: Toward clinical translation
    Itziar Gómez-Aguado, Julen Rodríguez-Castejón, Marina Beraza-Millor, Alicia Rodríguez‐Gascón, Ana del Pozo‐Rodríguez, Maria Ángelés Solinís · 2022 · International review of cytology
27. mRNA-Based Approaches to Treating Liver Diseases
    Maximiliano L. Cacicedo, María José Limeres, Stephan Gehring · 2022 · Cells
28. Gene therapy for organic acidemias: Lessons learned from methylmalonic and propionic acidemia
    Randy J. Chandler, Charles P. Venditti · 2023 · Journal of Inherited Metabolic Disease
29. Systemic Alanine Glyoxylate Aminotransferase mRNA Improves Glyoxylate Metabolism in a Mouse Model of Primary Hyperoxaluria Type 1
    Anjli Kukreja, Melissa A. Lasaro, Christian Cobaugh, Chris D. Forbes, Jianping Tang, Xiang Gao, Cristina Martín-Higueras, Angel Luis Pey, EDUARDO C. SALIDO, Susan B. Sobolov et al. · 2019 · Nucleic Acid Therapeutics
30. Hepatic glutamine synthetase augmentation enhances ammonia detoxification
    Leandro R. Soria, Matthew Nitzahn, Angela De Angelis, Suhail Khoja, Sergio Attanasio, Patrizia Annunziata, Donna J Palmer, Philip Ng, Gerald S. Lipshutz, Nicola Brunetti‐Pierri · 2019 · Journal of Inherited Metabolic Disease
31. Lipid‐based nucleic acid therapeutics with in vivo efficacy
    Md Abu Sufian, Marc Antoniu Ilies · 2022 · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology
32. In vivo genome editing at the albumin locus to treat methylmalonic acidemia
    Jessica L. Schneller, Ciaran M. Lee, Leah E. Venturoni, Randy J. Chandler, Ang Li, Sangho Myung, Thomas James Cradick, Ayrea E. Hurley, William R. Lagor, Gang Bao et al. · 2021 · Molecular Therapy — Methods & Clinical Development
33. The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA
    Laura Taina-González, María de la Fuente · 2022 · Pharmaceutics
34. mRNA-based therapies: Preclinical and clinical applications
    Musga Qureischi, Julia Mohr, Estibaliz Arellano-Viera, Sarah E. Knudsen, Farrukh Vohidov, Andoni Garitano-Trojaola · 2022 · International review of cytology
35. Methylmalonic acid induces inflammatory response and redox homeostasis disruption in C6 astroglial cells: potential glioprotective roles of melatonin and resveratrol
    Rômulo Rodrigo de Souza Almeida, Larissa Daniele Bobermin, Belisa Parmeggiani, Krista Minéia Wartchow, Diogo Onofre Souza, Carlos‐Alberto Gonçalves, Moaçir Wajner, Guilhian Leipnitz, André Quincozes‐Santos · 2022 · Amino Acids
36. RNA nanomedicine in liver diseases
    Anita K. Bakrania, Yulin Mo, Gang Zheng, Mamatha Bhat · 2023 · Hepatology
37. Unleashing the potential of mRNA therapeutics for inherited neurological diseases
    Edoardo Monfrini, Giacomo Baso, Dario Ronchi, Megi Meneri, Delia Gagliardi, Lorenzo Quetti, Federico Verde, Nicola Ticozzi, Antonia Ratti, Alessio Di Fonzo et al. · 2024 · Brain
38. Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression
    Matthias Zadory, Elliot Lopez, Samuel Babity, Simon‐Pierre Gravel, Davide Brambilla · 2022 · Biomaterials Science
39. The therapeutic landscape of citrin deficiency
    Toni Vukovic, Li Eon Kuek, Barbara Yu, Georgios Makris, Johannes Häberle · 2024 · Journal of Inherited Metabolic Disease
40. C3AR1 mRNA as a Potential Therapeutic Target Associates With Clinical Outcomes and Tumor Microenvironment in Osteosarcoma
    Tiannan Zou, Weibin Liu, Zeyu Wang, Jiayu Chen, Sheng Lu, Kun Huang, Weichao Li · 2021 · Frontiers in Medicine
41. Emerging mRNA Technology for Liver Disease Therapy
    Ji Wang, Yile Fang, Zhiqiang Luo, Jinglin Wang, Yuanjin Zhao · 2024 · ACS Nano
42. Navigating the next frontier in biomedicine: breakthroughs and insights in nucleic acid therapeutics
    Shanchao Wu, Zhihui Zhang, Zilong Zhao, Cheng Cui, Weihong Tan · 2026 · Chemical Science
43. NANOSPRESSO: toward personalized, locally produced nucleic acid nanomedicines
    Mariona Estapé Sentí, Alexandre Ceccaldi, Marta Luciani, Nadine Saber, Paul J. L. Schürmann, Maurits W. Geerlings, Peter Hölig, Joel de Beer, Michael Hannus, Fred Campbell et al. · 2025 · Frontiers in Science
44. Lipid nanoparticle-encapsulated mRNA therapy corrects serum total bilirubin level in Crigler-Najjar syndrome mouse model
    Jenny A. Greig, Joanna K Chorazeczewski, Vivek Chowdhary, Melanie K. Smith, Matthew Jennis, James C. Tarrant, Elizabeth L. Buza, Kimberly A. Coughlan, Paolo G.V. Martini, James M. Wilson · 2023 · Molecular Therapy — Methods & Clinical Development
45. Inborn errors of amino acid metabolism – from underlying pathophysiology to therapeutic advances
    Shira G. Ziegler, Jiyoung Kim, Jeffrey T. Ehmsen, Hilary J. Vernon · 2023 · Disease Models & Mechanisms
46. mRNA biotherapeutics landscape for rare genetic disorders
    V Rajesh Iyer, Praveen Reddy. P, Bhagyashree Kaduskar, Shivranjani C Moharir, Rakesh K. Mishra · 2024 · Journal of Biosciences
47. A constitutive knockout of murine carbamoyl phosphate synthetase 1 results in death with marked hyperglutaminemia and hyperammonemia
    Suhail Khoja, Matthew Nitzahn, Brian Truong, Jenna Lambert, Brandon Willis, Gabriella Allegri, Véronique Rüfenacht, Johannes Häberle, Gerald S. Lipshutz · 2019 · Journal of Inherited Metabolic Disease
48. Messenger RNA therapy as an option for treating metabolic disorders
    Randy J. Chandler · 2019 · Proceedings of the National Academy of Sciences
49. Treatment of Anderson-Fabry Disease
    Irene Simonetta, Antonino Tuttolomondo, Mario Daidone, Salvatore Miceli, Antonio Ventura Pinto · 2020 · Current Pharmaceutical Design
50. Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria
    Karol Marcela Córdoba, Irantzu Serrano-Mendioroz, Daniel Jericó, María Merino, Lei Jiang, Ana Sampedro, Manuel Alegre, Fernando José Corrales, Marı́a J. Garrido, Paolo G.V. Martini et al. · 2022 · Science Translational Medicine
51. 1-13C-propionate breath testing as a surrogate endpoint to assess efficacy of liver-directed therapies in methylmalonic acidemia (MMA)
    Irini Manoli, Alexandra R. Pass, Elizabeth A. Harrington, Jennifer L. Sloan, Jack Gagné, Samantha McCoy, Sarah Louise Bell, Jacob D. Hattenbach, Brooks P. Leitner, Courtney J. Duckworth et al. · 2021 · Genetics in Medicine
52. mRNA Treatment Rescues Niemann–Pick Disease Type C1 in Patient Fibroblasts
    Denzil L. Furtado, Christina Cortez‐Jugo, Ya Hui Hung, Ashley Ian Bush, Frank Caruso · 2022 · Molecular Pharmaceutics
53. Liver-directed gene-based therapies for inborn errors of metabolism
    Pasquale Piccolo, Alessandro Rossi, Nicola Brunetti‐Pierri · 2020 · Expert Opinion on Biological Therapy
54. Synthetic mRNA rescues very long-chain acyl-CoA dehydrogenase deficiency in patient fibroblasts and a murine model
    Xuejun Zhao, Al-Walid A. Mohsen, Stephanie J. Mihalik, Keaton J. Solo, Ermal Aliu, Huifang Shi, Shakuntala Basu, Catherine Kochersperger, Clinton Van’t Land, Anuradha Karunanidhi et al. · 2022 · Molecular Genetics and Metabolism
55. Modified mRNA Treatment Restores Cardiac Function in Desmocollin-2–Deficient Mouse Models of Arrhythmogenic Right Ventricular Cardiomyopathy
    Yan Zou, Jing Lu, Zhipeng Lian, Jianguo Jia, Juan Shen, Qianhe Li, Jennifer Ming Jen Wong, Kejia Jin, Wendi Yan, Xin-yue Ren et al. · 2025 · Circulation
56. Systemic gene therapy for methylmalonic acidemia using the novel adeno-associated viral vector 44.9
    Randy J. Chandler, Giovanni Di Pasquale, Jennifer L. Sloan, Samantha McCoy, Brandon T. Hubbard, Tina M. Kilts, Irini Manoli, John A. Chiorini, Charles P. Venditti · 2022 · Molecular Therapy — Methods & Clinical Development
57. Lipid-Based Colloidal Nanocarriers for Site-Specific Drug Delivery
    Kamyar Shameli, Behnam Naderi Kalali, Hassan Moeini, Aras Kartouzian · 2026 · Colloids and Interfaces
58. Advances in Development of mRNA-Based Therapeutics
    Lei Huang, Luyao Zhang, Weiwei Li, Shiqiang Li, Jianguo Wen, Hangwen Li, Zhongmin Liu · 2020 · Current topics in microbiology and immunology
59. The future of gene-targeted therapy for hereditary tyrosinemia type 1 as a lead indication among the inborn errors of metabolism
    Whitney S. Thompson, Gourish Mondal, Caitlin J. VanLith, Robert A. Kaiser, Joseph B. Lillegard · 2020 · Expert Opinion on Orphan Drugs
60. Novel mRNA therapy restores GALT protein and enzyme activity in a zebrafish model of classic galactosemia
    Britt Delnoy, Minela Haskovic, Jo M. Vanoevelen, Laura K.M. Steinbusch, Esther Naomi Vos, Kèvin Knoops, Luc J. I. Zimmermann, Marek J. Noga, Dirk J. Lefeber, Paolo G.V. Martini et al. · 2022 · Journal of Inherited Metabolic Disease
61. mRNA-based therapy proves superior to the standard of care for treating hereditary tyrosinemia 1 in a mouse model
    Maximiliano L. Cacicedo, Christine Weinl-Tenbruck, Daniel Frank, Sebastian Wirsching, Beate Katharina Straub, Jana Hauke, Jürgen G. Okun, Nigel Horscroft, Julia B. Hennermann, Fred Zepp et al. · 2022 · Molecular Therapy — Methods & Clinical Development
62. Milestones in treatments for inborn errors of metabolism: Reflections on Where chemistry and medicine meet
    Hilary J. Vernon, Irini Manoli · 2021 · American Journal of Medical Genetics Part A
63. Current status and future directions of liver transplantation for metabolic liver disease in children
    Jessica A. Eldredge, Winita Hardikar · 2023 · Pediatric Transplantation
64. Translational kinetic‐pharmacodynamics of mRNA‐6231, an investigational mRNA therapeutic encoding mutein interleukin‐2
    Ivana Liric Rajlic, Beatriz Guglieri-López, Nabeel Rangoonwala, Vijay D. Ivaturi, Linh M. Van, Simone Mori, Brian T. Wipke, Douglas S. Burdette, Husain Z. Attarwala · 2024 · CPT Pharmacometrics & Systems Pharmacology
65. Liver Transplantation for Propionic Acidemia
    Sophoclis P. Alexopoulos, Lea K. Matsuoka, Einar Thor Hafberg, Thomas M. Morgan, Cary W. Thurm, Matt Hall, Justin A. Godown · 2019 · Journal of Pediatric Gastroenterology and Nutrition
66. Harnessing miRNAs: A Novel Approach to Diagnosis and Treatment of Tuberculosis
    Ahmed Soliman Doghish, Ahmed I. Abulsoud, Yara A. Nassar, Sami Mohamed Nasr, Osama A. Mohammed, Mustafa Ahmed Abdel‐Reheim, Nehal I. Rizk, Radwa Hussein Lutfy, Sherif S. Abdel Mageed, Mohamed Sayed Ismail et al. · 2025 · Journal of Biochemical and Molecular Toxicology
67. Treatment of metabolic disorders using genomic technologies: Lessons from methylmalonic acidemia
    Leah E. Venturoni, Charles P. Venditti · 2022 · Journal of Inherited Metabolic Disease
68. The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize
    Mirosław Janowski, Anna Andrzejewska · 2022 · Molecular Therapy — Nucleic Acids
69. What Can RNA-Based Therapy Do for Monogenic Diseases?
    Luka A. Clarke, Margarida Duarte Amaral · 2023 · Pharmaceutics
70. Modified mRNA as a Treatment for Myocardial Infarction
    Yu Wang, Meiping Wu, Haidong Guo · 2023 · International Journal of Molecular Sciences
71. Leveraging Rational Protein Engineering to Improve mRNA Therapeutics
    Jeremiah D. Farelli, Kirtika H. Asrani, Cleo Isaacs, J. S. Debear, Mary R. Stahley, Anumeha Shah, Melissa A. Lasaro, Christopher J. Cheng, Romesh R. Subramanian · 2018 · Nucleic Acid Therapeutics
72. Exploring the Potential and Advancements of Circular RNA Therapeutics
    Lei Wang, Lianqing Wang, Chunbo Dong, Jialong Liu, Guoxin Cui, Shan Gao, Zhida Liu · 2025 · Exploration
73. Just Keep Rolling?—An Encompassing Review towards Accelerated Vaccine Product Life Cycles
    2023
74. Pharmaceutical strategies for optimized mRNA expression
    Yingying Shi, Jiapeng Mao, Sijie Wang, Siyao Ma, Lihua Luo, Jian You · 2024 · Biomaterials
75. In vivo demonstration of enhanced mRNA delivery by cyclic disulfide-containing lipid nanoparticles for facilitating endosomal escape
    Seigo Kimura, Kana Okada, Noriaki Matsubara, Fangjie Lyu, Susumu Tsutsumi, Yasuaki Kimura, Fumitaka Hashiya, Masahito Inagaki, Naoko Abe, Hiroshi Abe · 2025 · RSC Medicinal Chemistry
76. Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases
    Karol Marcela Córdoba, Daniel Jericó, Ana Sampedro, Lei Jiang, María J. Iraburu, Paolo G.V. Martini, Pedro Berraondo, Matias Antonio Avila, Antonio Fontanellas · 2022 · International review of cytology
77. Applications and challenges of biomaterial mediated mRNA delivery
    Huapan Fang, Qian Chen · 2022 · Exploration of Targeted Anti-tumor Therapy
78. Deciphering the biological fate of mRNA-LNP-based biologics: A perspective from tissue to intracellular distribution
    Xu, Xin, Cui, Lili, Zhang, Yong, Gu, Jingkai · 2026 · Acta Pharmaceutica Sinica B
79. Practical management of organic acidemias
    Kimberly A. Chapman · 2019 · Translational Science of Rare Diseases
80. Correction to: 1-13C-propionate breath testing as a surrogate endpoint to assess efficacy of liver-directed therapies in methylmalonic acidemia (MMA)
    Irini Manoli, Alexandra R. Pass, Elizabeth A. Harrington, Jennifer L. Sloan, Jack Gagné, Samantha McCoy, Sarah Louise Bell, Jacob D. Hattenbach, Brooks P. Leitner, Courtney J. Duckworth et al. · 2021 · Genetics in Medicine
81. mRNA therapy restores ureagenesis and corrects glutathione metabolism in argininosuccinic aciduria
    Sonam Gurung, Oskar Vilhelmsson Timmermand, Dany P.B. Perocheau, Ana Luisa Gil-Martínez, Magdalena Minnion, Loukia Touramanidou, Sherry Fang, Martina Messina, Youssef Khalil, Abigail R. Barber et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
82. Therapeutic Application of mRNA for Genetic Diseases
    Paul J. L. Schürmann, Stijn v. Breda Vriesman, Jose Castro-Alpízar, Sander A. A. Kooijmans, Edward E. S. Nieuwenhuis, Raymond Michel Schiffelers, Sabine A. Fuchs · 2025 · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology
83. Liver gene transfer for metabolite detoxification in inherited metabolic diseases
    Alfonso Manuel D’Alessio, Iolanda Boffa, Lucia De Stefano, Leandro R. Soria, Nicola Brunetti‐Pierri · 2024 · FEBS Letters
84. Beyond the present: current and future perspectives on the role of infections in pediatric PCD
    Megan Frohlich, Bernadette J. Prentice, Louisa Owens, Shafagh A. Waters, Lucy C. Morgan · 2025 · Frontiers in Pediatrics
85. Delivering the Message: Translating mRNA Therapy for Liver Inherited Metabolic Diseases
    Sonam Gurung, Dany P.B. Perocheau, Roopkatha Ghosh, Stephen L. Hart, Julien Baruteau · 2025 · Journal of Inherited Metabolic Disease
86. Association of maternal TSH and neonatal metabolism: A large prospective cohort study in China
    Qingzhi Hou, Hui Zou, Shuping Zhang, Jiujing Lin, Wenying Nie, Yazhou Cui, Sijin Liu, Jinxiang Han · 2022 · Frontiers in Endocrinology
87. Would, early, versus late hydroxocobalamin dose intensification treatment, prevent cognitive decline, macular degeneration and ocular disease, in 5 patients with early-onset cblC deficiency?
    Emmanuel Scalais, Christine Geron, Charlotte Pierron, Sandra Cardillo, Vincent Schlesser, Fréderic Mataigne, Patricia Borde, Luc Régal · 2023 · Molecular Genetics and Metabolism
88. The incidence of movement disorder increases with age and contrasts with subtle and limited neuroimaging abnormalities in argininosuccinic aciduria
    Sonam Gurung, Saketh R. Karamched, Dany P.B. Perocheau, Kiran K. Seunarine, Tomas Baldwin, Haya Alrashidi, Loukia Touramanidou, Claire E. Duff, Nour M. Elkhateeb, Karolina M. Stępień et al. · 2023 · Journal of Inherited Metabolic Disease
89. Base-modified factor VIII mRNA delivery with galactosylated lipid nanoparticles as a protein replacement therapy for haemophilia A
    Porkizhi Arjunan, Gokulnath Mahalingam, Priyanka Sankar, Durga Kathirvelu, Sevanthy Suresh, Sandya Rani, Kumarasamypet Murugesan Mohankumar, Saravanabhavan Thangavel, Srujan Kumar Marepally · 2024 · Biomaterials Science
90. Advances in RNA therapeutics for modulation of ‘undruggable’ targets
    Emily Martinsen, Tasmia Jinnurine, Saranya Subramani, Marie Rogne · 2024 · Progress in molecular biology and translational science
91. An Early Cost-Utility Model of mRNA-Based Therapies for the Treatment of Methylmalonic and Propionic Acidemia in the United Kingdom
    Pablo E. Bretos-Azcona, Matthew Wallace, Murvin Jootun, Guanyi Jin, Ion Agirrezabal, Ágota Szende · 2024 · Clinical Drug Investigation
92. mRNA as a medicine in nephrology: the future is now
    Simona Granata, Giovanni Stallone, Gianluigi Zaza · 2023 · Clinical Kidney Journal
93. Jet injection potentiates naked mRNA SARS-CoV-2 vaccine in mice and non-human primates by adding physical stress to the skin
    Saed Abbasi, Miki Matsui-Masai, Fumihiko Yasui, Akimasa Hayashi, Theofilus A. Tockary, Shiro Akinaga, Michinori Kohara, Kazunori Kataoka, Satoshi Uchida · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
94. Engineering Lipid Nanoparticles for Precision RNA Delivery: Design Principles, Targeting Strategies, and Clinical Prospects
    Yu Han, Ying Wang, Xintao Gao, Yan Lei, Yantao Li, Zhiyong Tang · 2026 · Cancer Nexus
95. Beyond the Sequence: Chemical and Topological Design and Innovations in mRNA Therapeutics
    Dangliang Liu, Hongyu Chen, Alisia Pan, Xiao Wang · 2026 · Chemical Reviews
96. mRNA Technology in Modern Medicine: Review and Future Prospects
    Heslley Machado Silva · 2025 · Clinical and Molecular Epidemiology
97. Polycations Improve Intracellular Stability of mRNA Delivered Using Lipid Nanoparticles for Prolonged Protein Expression
    Jumpei Norimatsu, Rashida Hashim, Theofilus A. Tockary, Muhammad Shahid Nazir, Yuki Mochida, Satoshi Uchida · 2025 · ACS Applied Nano Materials
98. Genome editing and cancer therapy: handling the hypoxia-responsive pathway as a promising strategy
    Emanuela Stampone, Debora Bencivenga, Maria Chiara Capellupo, Domenico Roberti, Immacolata Tartaglione, Silverio Perrotta, Fulvio Della Ragione, Adriana Borriello · 2023 · Cellular and Molecular Life Sciences
99. Systemic Administered mRNA as Therapy for Metabolic Diseases
    Hervé Puy, Jean‐Charles Deybach, Laurent Gouya · 2018 · Trends in Molecular Medicine
100. Central nervous system-targeted adeno-associated virus gene therapy in methylmalonic acidemia
     Francis J. May, PamelaSara E. Head, Leah E. Venturoni, Randy J. Chandler, Charles P. Venditti · 2021 · Molecular Therapy — Methods & Clinical Development